SCHEMBL6938906

SCHEMBL6938906

CC(N)CCc1ccccn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.57
CYP1A2 P05177 4/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP2C19 P33261 1/20 0.53
HRH3 Q9Y5N1 1/20 0.52
LMNA P02545 2/20 0.50
TAAR1 Q96RJ0 1/20 0.50
ALOX15 P16050 1/20 0.50
GRIN2D O15399 1/20 0.49
GRIN3B O60391 1/20 0.49
GRIN1 Q05586 1/20 0.49
GRIN2A Q12879 1/20 0.49
GRIN2B Q13224 1/20 0.49
GRIN2C Q14957 1/20 0.49
GRIN3A Q8TCU5 1/20 0.49
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
CA12 O43570 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10771160 1.00 HRH1 (0.57) HRH1CYP1A2ALDH1A1CYP2C19HRH3
SCHEMBL10398781 0.89 HRH1 (0.56) HRH1CYP1A2ALDH1A1CYP2C19HRH3
SCHEMBL11877576 0.89 HRH1 (0.56) HRH1CYP1A2ALDH1A1CYP2C19HRH3
SCHEMBL19079581 0.85 HRH1 (0.53) HRH1CYP1A2ALDH1A1CYP2C19HRH3
SCHEMBL30201139 0.84 CYP1A2 (0.61) HRH1CYP1A2ALDH1A1CYP2C19HRH3
SCHEMBL574013 0.84 CYP1A2 (0.61) HRH1CYP1A2ALDH1A1CYP2C19HRH3
SCHEMBL7995690 0.81 HRH1 (0.53) HRH1CYP1A2ALDH1A1CYP2C19HRH3
SCHEMBL21510401 0.81 HRH1 (0.53) HRH1CYP1A2ALDH1A1CYP2C19HRH3
SCHEMBL659774 0.81 CYP1A2 (0.50) HRH1CYP1A2ALDH1A1CYP2C19HRH3
SCHEMBL8662285 0.81 CYP1A2 (0.53) HRH1CYP1A2ALDH1A1CYP2C19HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355695-A1 SMYD Inhibitors Epizyme, Inc. (US) 2017-12-14 US disclosed
US-20170190676-A1 Isoxazole Carboxamide Compounds Epizyme, Inc. (US) 2017-07-06 US disclosed
EP-1296938-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE Pfizer Limited (GB) 2003-04-02 EP disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 US disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190676-A1 Isoxazole Carboxamide Compounds SMYD3, SMYD2, SNRPD3 HRH1 978/4885CYP1A2 2329/4885ALDH1A1 1259/4885
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 HRH1 1444/4885CYP1A2 2135/4885ALDH1A1 1319/4885
US-20170355695-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 HRH1 2071/4885CYP1A2 3400/4885ALDH1A1 1533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.